Jianhua Shi

机构：First Affiliated Hospital of Xi'an Jiaotong University · ORCID：0000-0002-5351-406X

发表论文 138 篇 · 总被引 6524 次 · h-index 31

代表论文

• VCF2Dis: an ultra-fast and efficient tool to calculate pairwise genetic distance and construct population phylogeny from VCF files (2025 · GigaScience · 被引 55)
• Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR ‐mutated, advanced non‐small cell lung cancer: data from a randomized phase III trial (AENEAS) (2024 · 癌症：英文版 · 被引 28)
• Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study (2024 · Journal for ImmunoTherapy of Cancer · 被引 26)
• Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 study (2025 · The Lancet Respiratory Medicine · 被引 16)
• Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial (2024 · Signal Transduction and Targeted Therapy · 被引 16)
• First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trial (2024 · Med · 被引 16)